Idorsia announces a change to commercial leadership
Ad hoc announcement pursuant to Art. 53 LR Simon Jose to step down from his
position as Chief Commercial Officer and member of the Idorsia Executive
Committee to pursue other opportunities Otto Schwarz will advise the management
team on commercial operations
Allschwil, Switzerland – M ay 3 0 , 2023
Idorsia Ltd (SIX: IDIA) today announced that Simon Jose will leave his
position as Chief Commercial Officer and member of the Idorsia Executive
Committee to pursue other opportunities. Otto Schwarz has agreed to advise the
management team on commercial operations from July 1, 2023.
Jean-Paul Clozel, MD and Chief Executive Officer of Idorsia commented:
“Simon has made a significant contribution to Idorsia, establishing our
commercial organization from scratch, while preparing two products for launch
in different geographies. He leaves a solid foundation for the Idorsia team to
build on, and I wish him every success with his future.”
Jean-Paul Clozel continued:
“The task ahead of us is to translate the excellent prescriber and patient
feedback, as well as the solid demand for QUVIVIQ into a global commercial
success and bring the company to sustainable profitability. Having worked with
Otto Schwarz at Actelion and as a consultant for commercialization of
daridorexant in the early days of Idorsia, I have absolute confidence that he
is the right person to provide a fresh perspective and help the management team
steer our commercialization efforts.”
About Otto Schwarz
Otto is a highly accomplished industry executive with more than 35 years of
experience. He has launched multiple major specialty products on a global
basis. Most recently, Otto served as Executive Vice President, Chief Operating
Officer and a member of the Actelion Executive Committee, until the acquisition
of Actelion by Johnson & Johnson.
Prior to Actelion, Otto also served as Executive Vice-President Commercial
Operations at Nycomed, and Executive Board Member at Altana Pharma. He also
spent almost 20 years with Schering-Plough and Eli Lilly in Switzerland,
Canada, the US and Germany.
Otto Schwarz is an Austrian citizen and has a PhD in pharmaceutical chemistry
from Vienna University.
Notes to the editor
About Idorsia
Idorsia Ltd is reaching out for more – We have more ideas, we see more
opportunities and we want to help more patients. In order to achieve this, we
will develop Idorsia into a leading biopharmaceutical company, with a strong
scientific core.
Headquartered near Basel, Switzerland – a European biotech-hub – Idorsia is
specialized in the discovery, development and commercialization of small
molecules to transform the horizon of therapeutic options. Idorsia has a
20-year heritage of drug discovery, a broad portfolio of innovative drugs in
the pipeline, an experienced team of professionals covering all disciplines
from bench to bedside, and commercial operations in Europe, Japan, and the US –
the ideal constellation for bringing innovative medicines to patients.
Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June
2017 and has over 1,300 highly qualified specialists dedicated to realizing our
ambitious targets.
For further information, please contact
Andrew C. Weiss
Senior Vice President, Head of Investor Relations & Corporate Communications
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil
+41 58 844 10 10
investor.relations@idorsia.com
media.relations@idorsia.com
www.idorsia.com
The above information contains certain 'forward-looking statements', relating
to the company's business, which can be identified by the use of
forward-looking terminology such as 'estimates', 'believes', 'expects', 'may',
'are expected to', 'will', 'will continue', 'should', 'would be', 'seeks',
'pending' or 'anticipates' or similar expressions, or by discussions of
strategy, plans or intentions. Such statements include descriptions of the
company's investment and research and development programs and anticipated
expenditures in connection therewith, descriptions of new products expected to
be introduced by the company and anticipated customer demand for such products
and products in the company's existing portfolio. Such statements reflect the
current views of the company with respect to future events and are subject to
certain risks, uncertainties and assumptions. Many factors could cause the
actual results, performance or achievements of the company to be materially
different from any future results, performances or achievements that may be
expressed or implied by such forward-looking statements. Should one or more of
these risks or uncertainties materialize, or should underlying assumptions
prove incorrect, actual results may vary materially from those described herein
as anticipated, believed, estimated or expected.
Anhang Medienmitteilung PDF